The bill amends the "Uniform Controlled Substances Act" to update and clarify definitions related to controlled substances, particularly focusing on pain management and opioid prescriptions. Key insertions include new definitions for "acute pain," "chronic intractable pain," and "chronic pain," which specify criteria based on duration and severity. The bill also introduces terms like "opioid therapy" and "therapeutic purpose," emphasizing responsible prescribing practices. Notably, it modifies existing language by changing "A practitioner" to "Practitioners" to encompass all qualified individuals and removes outdated terms such as "opiates," replacing them with "opioids." Additionally, it mandates that practitioners prescribe the lowest effective dosage of immediate-release opioids and document the medical necessity for opioid prescriptions, especially for minors.

Furthermore, the bill repeals certain sections of the current law, including definitions related to controlled substances, and introduces a new definition section that will be effective until January 1, 2023. It removes specific criteria for determining imitation controlled substances and eliminates the requirement for practitioners to be eligible for reimbursement from health insurance carriers when prescribing for chronic intractable pain. The bill emphasizes the importance of maintaining accurate records and outlines the circumstances under which practitioners may face disciplinary action for improper prescribing. Overall, the amendments aim to enhance the regulation of controlled substances, ensuring alignment with current medical practices while improving patient safety and accountability in prescribing practices.